Drug Profile
Research programme: CNS disorders therapeutics - Ocuphire Pharma
Alternative Names: RX-10,000Latest Information Update: 13 Nov 2020
Price :
$50
*
At a glance
- Originator Revaax Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Neurological disorders; Neuropathic pain
Most Recent Events
- 05 Nov 2020 Rexahn Pharmaceuticals has been merged with Ocuphire Pharma to form Ocuphire Pharma
- 19 May 2005 Preclinical trials in Anxiety disorders in USA (unspecified route)
- 19 May 2005 Preclinical trials in Cognition disorders in USA (unspecified route)